© The Rockefeller University Press, 0022-1007/1997/3/1005/ $5.00
The Journal of Experimental Medicine, Volume 185, Number 6, March 17, 1997 1005-1012
Interleukin-18 (Interferon-
–inducing Factor) Is Produced by Osteoblasts and Acts Via Granulocyte/Macrophage Colony-stimulating Factor and Not Via Interferon- to Inhibit Osteoclast Formation
Nobuyuki Udagawa*,
Nicole J. Horwood*,
Jan Elliott*,
Alan Mackay
,
Jane Owens,
Haruki Okamura
,
Masashi Kurimoto¶,
Timothy J. Chambers,
T. John Martin*, and
Matthew T. Gillespie*
From the * St. Vincent's Institute of Medical Research and The University of Melbourne, Department of Medicine, St. Vincent's Hospital, Fitzroy, Victoria 3065, Australia; Department of Histopathology, St. George's Hospital Medical School, London SW17 ORE, United Kingdom; Department of Bacteriology, Hyogo College of Medicine, Nishinomiya 663, Japan; and ¶ Fujisaki Institute, Hayashibara Biochemical Laboratories Incorporated, Okayama 702, Japan
 |
Abstract
|
|---|
We have established by differential display polymerase chain reaction of mRNA that interleukin (IL)-18 is expressed by osteoblastic stromal cells. The stromal cell populations used for comparison differed in their ability to promote osteoclast-like multinucleated cell (OCL) formation. mRNA for IL-18 was found to be expressed in greater abundance in lines that were unable to support OCL formation than in supportive cells. Recombinant IL-18 was found to inhibit OCL formation in cocultures of osteoblasts and hemopoietic cells of spleen or bone marrow origin. IL-18 inhibited OCL formation in the presence of osteoclastogenic agents including 1
,25-dihydroxyvitamin D3, prostaglandin E2, parathyroid hormone, IL-1, and IL-11. The inhibitory effect of IL-18 was limited to the early phase of the cocultures, which coincides with proliferation of hemopoietic precursors. IL-18 has been reported to induce interferon-
(IFN-) and granulocyte/macrophage colony-stimulating factor (GM–CSF) production in T cells, and both agents also inhibit OCL formation in vitro. Neutralizing antibodies to GM–CSF were able to rescue IL-18 inhibition of OCL formation, whereas neutralizing antibodies to IFN- did not. In cocultures with osteoblasts and spleen cells from IFN- receptor type II–deficient mice, IL-18 was found to inhibit OCL formation, indicating that IL-18 acted independently of IFN- production: IFN- had no effect in these cocultures. Additionally, in cocultures in which spleen cells were derived from receptor-deficient mice and osteoblasts were from wild-type mice and vice versa, we identified that the target cells for IFN- inhibition of OCL formation were the hemopoietic cells. The work provides evidence that IL-18 is expressed by osteoblasts and inhibits OCL formation via GM–CSF production and not via IFN- production.
Address correspondence to Dr. M.T. Gillespie, St. Vincent's Institute of Medical Research, 41 Victoria Parade, Fitzroy 3065, Victoria, Australia.
In the process of osteoclast formation, there is an absolute requirement for cell to cell contact between osteoclastic precursor cells of hemopoietic origin and bone marrow stromal or osteoblastic cells to commit the hemopoietic cell towards osteoclast development (1–3). The osteoclast is a large multinucleated giant cell that contains between 2 and 100 nuclei per cell, expresses tartrate-resistant acid phosphatase (TRAP)1 activity and calcitonin receptors, has the ability to form resorption pits on bone or dentine slices and differs from macrophage polykaryons (4). We developed a coculture system of mouse hematopoietic and primary osteoblastic stromal cells with which to investigate osteoclast development in vitro. In this coculture system, osteoclastlike cells (OCL) are produced in response to a number of systemic or local factors, including 1,25-dihydroxyvitamin D3 (1,25(OH)2 D3), prostaglandin E2 (PGE2), parathyroid hormone (PTH), or the interleukins (IL-1, IL-6, and IL-11) (1, 5–7). Generation of these OCLs requires that the osteoblastic and hemopoietic cells are cultured on the same surface (8). These cells are multinucleated and express the OCL characteristics of TRAP activity and calcitonin receptors, and have the capacity to resorb bone (8). In short, they display the properties of mature bona fide osteoclasts. However, the production of such OCLs in cocultures can be inhibited by a number of interleukins (e.g., IL-4, IL-10, and IL-13) and IFN- and GM-CSF (9–17).
We previously reported that bone marrow–derived stromal cell lines, MC3T3-G2/PA6 and ST2, had the capacity to support OCL formation in cocultures with hemopoietic cells (18). Recently, we established several bone marrow– derived stromal cell lines from a transgenic mouse and immortalized with a temperature-sensitive variant of the SV40 large T antigen; these cell lines differ in their OCLinductive ability (19, 20). To identify osteoblastic genes that are involved in the process of osteoclastogenesis, we have used differential display PCR (ddPCR) (21) to compare the mRNA populations between OCL-inductive and noninductive cell lines. Using this approach, we identified a recently discovered cytokine, IL-18 (IFN-–inducing factor) (22, 23), as a product of osteoblastic stromal cells. Using recombinant IL-18 we showed that it inhibits OCL formation, and we investigated its mode of action.
|
Materials and Methods
|
|---|
Animals, Cell Lines, and Drugs.
Newborn (0–1-d-old) C57BL/6J mice and 6–9-wk-old male C57BL/6J mice were purchased from Monash University Animal Services Centre (Clayton, Australia). We thank Professor M. Auget (Swiss Institute for Experimental Cancer Research, Switzerland) and Dr. P. Tipping (Monash Medical Centre, Australia) for access to the IFN- type II receptor knockout mice (IFN- R–/–) (24). The murine stromal cell lines, tsJ2, tsJ10, and tsJ14, were generated by transfection with a retroviral vector expressing a temperature-sensitive variant of the immortalizing gene of SV40 (tsA58; 19, 20). 1,25(OH)2 D3 was purchased from Wako Pure Chemical Co. (Osaka, Japan). PGE2 was obtained from Sigma Chem. Co. (St. Louis, MO). Recombinant mouse IL-18 and rabbit polyclonal antibodies to mouse IL-18 were prepared as described (22). Recombinant mouse IFN- was a gift from Dr. J.A. Hamilton (Department of Medicine, Royal Melbourne Hospital, Australia). Recombinant mouse IL-1β, mouse GM–CSF, and anti-mouse GM–CSF polyclonal antibody were purchased from R&D Systems (Minneapolis, MN). Recombinant human IL-11 was obtained from Dr. T. Willson (Walter and Eliza Hall Institute, Australia). Other chemicals and reagents were of analytical grade.
Coculture System.
Osteoblastic cells were prepared from the calvaria of newborn mice by digestion with 0.1% collagenase (Worthington Biochemical Co., Freefold, Australia) and 0.2% dispase (Godo Shusei, Tokyo, Japan). Bone marrow and spleen cells were obtained from adult and from newborn mice, respectively (6). Osteoblastic cells were cocultured with bone marrow or spleen cells as described (6, 25, 26). In short, primary osteoblastic cells (2 x 104 per well) and nucleated spleen cells (1 x 106 per well) or marrow cells (5 x 105 per well) were cocultured in 48-well plates (Corning Glass Inc., Corning, NY) with 0.4 ml of -MEM (GIBCO BRL, Gaithersburg, MD) containing 10% fetal bovine serum (Cytosystems, Castle Hill, New South Wales, Australia) in the presence of test chemicals. Cultures were incubated in quadruplicate and cells were replenished on day 3 with fresh medium. OCL formation was evaluated after culturing for 6 to 7 d. Adherent cells were fixed and stained for TRAP, and the number of TRAP-positive OCLs was scored as described (6). For TRAP staining, adherent cells were fixed with 4% formaldehyde in PBS for 3 min. After treatment with ethanol/acetone (50:50 vol/vol) for 1 min, the well surface was air dried and incubated for 10 min at room temperature in an acetate buffer (0.1 M sodium acetate, pH 5.0) containing 0.01% naphthol AS-MX phosphate (Sigma) as a substrate and 0.03% red violet LB salt (Sigma) as a stain for the reaction product in the presence of 50 mM sodium tartrate. TRAPpositive cells appeared dark red. The expression of calcitonin receptors was also assessed by autoradiography using [125I]salmon calcitonin as described (25).
Differential Display PCR.
Total cellular RNA was extracted from cell lines or mouse tissues using guanidine thiocyanate–phenol chloroform and used for reverse transcriptase PCR (RTPCR) essentially as described (27, 28). Differential display PCR (ddPCR) was performed essentially as described (21, 28), except 1 µg of total RNA was reverse transcribed. PCR products were cloned into pCRScript II (Stratagene, La Jolla, CA) or pGEM-T (Promega, Madison, WI). DNA sequence analysis was performed using a T7 sequencingTM kit (Pharmacia Biotech, Uppsala, Sweden). Oligonucleotides were synthesized on an Oligo 1,000M DNA Synthesizer (Beckman Instruments, Inc., Fullerton, CA). The oligonucleotides were the following: for ddPCR, DDMR-2 (5'-CTTGATTGCC-3') and T12VA (5'-TTTTTTTTTTTT [A,C,G]A-3'); for IL-18 amplification, IL-18-1 (sense strand oligonucleotide 5'-ACTGTACAACCGCAGTAATACGG-3', nucleotides 286–308 Fig. 1 B) and IL-18-2 (antisense strand oligonucleotide 5'-GGGTATTCTGTTATGGAAATACAGG-3', nucleotides 804–828; Fig. 1 B), and IL-18-3 (sense strand oligonucleotide 5'-TTGCCAAAAGGAAGATGATG-3', nucleotides 641–660; Fig. 1 B) served as internal oligonucleotide probe for hybridization studies as described (27, 28); mouse glyceraldehyde3-phosphate dehydrogenase (GAPDH) primers were GAPDH-1, GAPDH-2 (5'-ATGAGGTCCACCACCCTGTT-3', nucleotides 640–659; 29), and GAPDH-4 as described (30).
View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Identification of IL-18. (A) An example of a ddPCR gel. Lanes correspond to RNA from the different sources: (lane 1) hydrocortisone-treated tsJ10 cells, (lane 2) hydrocortisone-treated tsJ14 cells, (lane 3) 1,25(OH)2 D3- and PGE2treated tsJ2 cells, and (lane 4) 1,25(OH)2 D3- and PGE2treated tsJ14 cells. The PCR fragment identified as IL-18 is indicated by the arrow on the left. Indicated by the arrow on the right is a PCR fragment corresponding to a hitherto uncharacterized mRNA species, which is expressed in greater abundance in the OCL-supportive cell lines. The osteoclast-supporting activity (OSA) of these cell lines is indicated below the gel: plus (supportive) or minus (nonsupportive). (B) Nucleotide sequence of mouse IL-18 (GenBankTM accession number D49949). The region corresponding to the differentially expressed PCR fragment isolated from (A) is between nucleotides 636–830. Sequences underlined correspond to oligonucleotides specific to IL-18 used for RT-PCR analysis and detection of RT-PCR products (IL-18-1, IL-18-3, and IL-18-2 from 5' to 3'). Nucleotides in capitals corrrespond to the coding region of IL-18, whereas those in lower case correspond to the 5' and 3' untranslated sequences. (C) Semiquantitative RT-PCR analysis of IL-18 mRNA. PCR products for RNA isolated from different sources was reversed transcribed with oligo (dT) and PCR performed with the primers IL-18-1 and IL-18-2 for 23 cycles, which was in the log-linear range of amplification. Lanes correspond to RNA from (1) hydrocortisone-treated tsJ10 cells, (2) hydrocortisone-treated tsJ14 cells, (3) 1,25(OH)2 D3- and PGE2-treated tsJ2 cells, and (4) 1,25(OH)2 D3- and PGE2-treated tsJ14 cells. Resultant PCR products were electrophoresed, transferred to a nylon membrane, and hybridized with a -32P–labeled internal detection oligonuleotide for IL-18 (IL-18-3). Similar amplifications for GAPDH with GAPDH-2 and GAPDH-4 for 20 cycles were performed and products detected with -32P–labeled GAPDH-1 as previously described (30). The osteoclast-supporting activity (OSA) of these cell lines is indicated below the gel: plus (supportive) or minus (nonsupportive).
| |
|
Results
|
|---|
Identification of IL-18 mRNA.
To identify stromal cell genes potentially involved in osteoclastogenesis, we have used differential display of eukaryotic mRNA (ddPCR) (21) to identify genes differentially expressed between osteoclastogenic supportive and nonsupportive stromal cell lines. The stromal cell lines were established after immortalization with large T antigen (19, 20) and were stable in their phenotype. The cell lines tsJ2 and tsJ10 could support OCL formation after hydrocortisone (10–6 M) or PGE2 (10–7 M) and 1,25(OH)2 D3 (10–8 M) treatment. However, in the absence of hydrocortisone or PGE2 and 1,25(OH)2 D3, the tsJ2 and tsJ10 cell lines were unable to support OCL formation. In contrast, the tsJ14 cell line was unable to support osteoclast formation even in the presence of hydrocortisone or PGE2 and 1,25(OH)2 D3.
RNA was extracted from OCL-inductive lines (tsJ10 treated with hydrocortisone and tsJ2 treated with PGE2 and 1,25(OH)2 D3) and from the OCL-noninductive cells (tsJ14 treated with hydrocortisone or with PGE2 and 1,25(OH)2 D3) and subjected to ddPCR analysis. Using an array of anchored 3' primers (T12VA, T12VC, T12VG, or T12VT; where V = A, C, and G) and defined 10-mer primers (which act as 5' primers), several mRNA species appeared to be expressed in a manner consistent with either an OCL-inductive or inhibitory phenotype (see Fig. 1 A). Using the anchored 3' primer (T12VA) and the 5' primer DDMR-2, a mRNA species was found to be upregulated in OCL-inductive cells (tsJ10 cells treated with hydrocortisone and tsJ2 cells treated with PGE2 and 1,25 OH)2 D3; Fig. 1 A, lanes 1 and 3; arrowed at right) with respect to the OCL-noninductive cells (tsJ14 cells treated with hydrocortisone or PGE2 and 1,25(OH)2 D3; Fig. 1 A, lanes 2 and 4); this mRNA was unique, sharing no identity with sequences in the GenBankTM database, and is currently being analyzed. This primer pair also amplified a mRNA species, which was upregulated in OCL-nonsupportive cells (tsJ14 treated with hydrocortisone; Fig. 1 A, lane 2) compared with OCL-supportive cells (tsJ10 cells treated with hydrocortisone; Fig. 1 A, lane 1). This band of 195 bp was extracted, cloned, and sequenced and was identified as mouse IFN–inducing factor (IL-18) (22, 23). The RT-PCR–generated fragment was derived from the 3' end of the mRNA for IL-18, indicating that the anchored PCR primer had primed near the poly(A) tail (Fig. 1 B). Additionally, the degenerate 10-mer 5' primer DDMR-2 only differed by one nucleotide from that of the IL-18 cDNA sequence (Fig. 1 B, at nucleotide 640, A versus C, respectively). The band designated by IL-18 in Fig. 1 A appeared to be enhanced by PGE2 and 1,25(OH)2 D3 as indicated by the amount of amplified product resulting from PCR of RNA from cells treated with these agents (Fig. 1 A, lanes 3 and 4); however, this was complicated by coamplification of another mRNA species under these treatment conditions. Thus, the designated band corresponding to amplified IL-18 cDNA in Fig. 1 A was composed of at least two distinct mRNA species.
To confirm differential expression of IL-18 mRNA in cell lines that were OCL-inductive rather than noninductive, semiquantitative RT-PCR using IL-18–specific oligonucleotides (IL-18-1 and IL-18-2) was undertaken and the PCR product was confirmed by an internal specific oligonucleotide for IL-18 (IL-18-3) (Fig. 1 C). IL-18 mRNA levels were found to be higher in the OCL-noninductive cells (Fig. 1 C, lanes 2 and 4) than the inductive cells (Fig. 1 C, lanes 1 and 3). Quantitation by phosphorimager analysis revealed that IL-18 levels were three- and sevenfold higher in the OCL-noninductive cells (Fig. 1 C, lanes 2 and 4, respectively) than the OCL-inductive cells (Fig. 1 C, lanes 1 and 3). Additionally, semiquantitive RT-PCR established that IL-18 mRNA was expressed in a variety of tissues including brain, heart, liver, lung, spleen, and skeletal muscle (data not shown).
IL-18 Inhibits Osteoclast Formation In Vitro.
IL-18 was originally identified because of its effect on IFN- production, and hence it was originally called interferon-–inducing factor (IGIF) (22). The name was subsequently changed to IL-18 (23). Because IFN- is a potent inhibitor of osteoclastogenesis (10, 13, 14, 31), and IL-18 mRNA levels were elevated in cells with an OCL-noninductive phenotype, we sought to identify whether IL-18 affects osteoclastogenesis via IFN- production. We examined TRAP-positive OCL formation in cocultures of mouse bone marrow and osteoblastic cells. OCLs were formed in cocultures where PGE2 and 1,25(OH)2 D3 were added; without at least one of these agents, no OCLs were formed (Fig. 2 A). Autoradiographic study using labeled calcitonin revealed that TRAP-positive multinucleated and mononuclear cells formed in these cocultures possessed calcitonin receptors (data not shown). Recombinant mouse IL-18 dose-dependently inhibited OCL formation, giving maximal inhibition at 8 ng/ml (Fig. 2 A); this dose response to IL-18 is very similar to that in other biological systems (22). Recombinant mouse IFN- dosedependently inhibited OCL formation with maximal inhibition at 50 U/ml (Fig. 2 B), confirming previous observations in mouse bone marrow cultures (10). In subsequent experiments, IL-18 was used at 10 ng/ml and IFN- at 50 U/ml. OCL formation can be enhanced by a number of agents that act through different second messenger systems (e.g., vitamin D receptor, cAMP, and gp130) (1). To examine whether the inhibitory actions of IL-18 on OCL formation was stimulator specific or whether it acted as a general inhibitor, IL-18 was added to cocultures with the osteoclastogenic agents 1,25(OH)2 D3, PGE2, PTH, or IL-11. IL-18 or IFN- inhibited OCL formation induced by each of these agents of osteoclastogenesis (Fig. 3).
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Effect of IL-18 (10 ng/ml) on OCL formation in cocultures of mouse bone marrow and osteoblastic cells in the presence of 1,25(OH)2 D3 (10–8 M), PGE2 (10–7 M), PTH (200 ng/ml), IL-11 (20 ng/ml), and IL-1 (100 ng/ml). After culture for 7 d, TRAP-positive OCLs were counted. Data are expressed as the means ± SEM of quadruplicate cultures and are representative of three similar experiments.
| |
IL-18 Inhibits the Early Stage of OCL Formation.
Next, we addressed the action of IL-18 and IFN- on the process of OCL formation. Treatment of cocultures revealed that the inhibitory actions of IL-18 on OCL formation occurred during the first 3 d of coculture (proliferating period), whereas IL-18 had no effect during the last 3 d of coculture (Fig. 4). In contrast, although IFN- inhibited OCL formation over the entire coculture period (days 0–6), it inhibited OCL formation by 50% during both the proliferating period (days 0–3) and the differentiation phase (days 3–6) (Fig. 4). These results suggested a fundamental difference between the inhibitory effects of IL-18 and IFN-, although potential stimulation of IFN- production by IL-18 could not be excluded by these experiments alone.
IL-18 Acts by Inhibitory Mechanism Distinct from IFN-.
Next, we sought to distinguish the inhibitory mechanisms of IL-18 and IFN- by using neutralizing antibodies to either IL-18 or IFN- in coculture experiments. We initially titrated the two antibodies (-IL-18 antibody or -IFN- antibody) and determined the concentration at which each antibody could rescue either IL-18–induced inhibition of OCL formation (for -IL-18 antibody) or IFN-–induced inhibition of OCL formation (for -IFN- antibody). A polyclonal neutralizing IL-18 antibody (at 30 µg/ml) rescued IL-18 inhibition of OCL formation (Fig. 5 A), however, this antibody (at 30 µg/ml) did not rescue the IFN- inhibition of OCL formation (Fig. 5 A). Because IFN- was speculated to be a downstream effector molecule of IL-18, we did not expect the neutralizing IL-18 antibody to rescue IFN- inhibition of OCL formation. The monoclonal IFN- neutralizing antibody at very low concentration (1 ng/ml) rescued IFN- inhibitory effects, whereas even at 2,000-fold excess of the IFN- rescuing concentration (20 µg/ml) it did not protect against IL-18 inhibition of OCL formation (Fig. 5 B). The inability of the IFN-–neutralizing antibody to rescue OCL formation after IL-18 treatment further suggested that IL-18 was not acting through IFN-. Finally, we made use of IFN- R–/–) mice (24). Cocultures of osteoblastic cells and spleen cells derived from the IFN- R–/– mouse were treated with either IL-18 or IFN-. IFN-, as expected, was unable to elicit an inhibition of OCL formation in these cocultures due to the absence of its cognate receptor on any cells (Fig. 6). In contrast, IL-18 inhibited OCL formation in these cocultures in a dose-dependent manner with a maximal effect at 10 ng/ml (Fig. 6), which is similar to normal mice cocultures as described above (see Fig. 2 A). This served as definitive proof that IL-18, although capable of inducing IFN- (a known inhibitor of OCL formation), mediated its inhibitory action on OCLs via an IFN-–independent mechanism.
IFN- Effects on OCL Formation in Cocultures from IFN- R–/– Mouse.
The IFN- R–/– mouse also provided a unique opportunity to address which cells in the cocultures were sensitive to the actions of IFN-. We performed cocultures using osteoblastic cells from the IFN- R–/–mouse with spleen cells from a normal C57BL/6J mouse and the reciprocal experiment, that is, osteoblastic cells from a normal mouse with spleen cells from the IFN- R–/– mouse, and treated these cocultures with IL-18 or IFN- (Fig. 7). As expected, IL-18 inhibited OCL formation under both culture regimes. However, IFN- inhibited OCL formation when cocultures were performed with normal spleen cells and osteoblasts from IFN- R–/– mice, but did not inhibit OCL formation in cocultures using normal osteoblasts with spleen cells from IFN- R–/– mice. These results indicated that IFN- acts specifically on osteoclastic precursors in spleen cells to inhibit osteoclast formation and not via the osteoblastic/stromal cells.
IL-18 Inhibits OCL Formation Via GM–CSF.
In addition to enhancing IFN- production, IL-18 has been shown to induce GM–CSF production in mitogen-stimulated peripheral blood mononuclear cells (23). Like IFN-, GM– CSF is a potent inhibitor of osteoclast formation in the mouse system (16, 26, 32–34), suggesting that GM–CSF may also be a candidate molecule involved in the IL-18 inhibition of OCL formation. Recombinant mouse GM– CSF (0.1 ng/ml) was found to inhibit OCL formation in this coculture system (Fig. 8). Thus, we examined whether a neutralizing antibody to GM–CSF could rescue the inhibitory effect of IL-18 on OCL formation. The polyclonal antibody (at 10 µg/ml) alone had no effect on OCL formation, but did indeed rescue OCL formation from the inhibitory actions of GM–CSF and those of IL-18 (Fig. 8). Moreover, the concentration of this antibody (0.1–1.0 µg/ml) to rescue OCL formation as a result of GM–CSF or IL-18 inhibition was similar. The neutralizing antibody to GM– CSF (10 µg/ml) was unable to rescue the IFN- inhibition of OCL formation (Fig. 8). This result, combined with the previous experiments, indicates that IL-18 most likely inhibits OCL formation by increasing the production of GM–CSF, a known inhibitor of OCL formation, and not via IFN-.
|
Discussion
|
|---|
In this report, we establish that a recently discovered cytokine, IL-18, can inhibit OCL formation in mouse cocultures. Elevated expression of mRNA for IL-18 was observed in stromal cell lines that were unable to support OCL formation, and recombinant IL-18 was a potent inhibitor of OCL formation in vitro. The discovery of IL-18 resulted from its ability to induce IFN- production by T cells (22). Although IFN- is known to inhibit osteoclast formation in vitro (4), the present experiments exclude IFN- as an intermediate in the inhibitory effect of IL-18 on osteoclast formation, for a number of reasons.
First, antibodies against IFN- failed to rescue IL-18 inhibition of OCL formation in cocultures, although they were able to prevent the effect of IFN- itself. Second, in our experiments with cells from type II IFN- R–/– mice, IL-18 still manifested its inhibitory action on osteoclast formation. Furthermore, an effect of IL-18 had no effect on the production of macrophages in vitro (Udagawa, N., and J.A. Hamilton, unpublished data), nor did IL-18 influence bone resorption by freshly isolated osteoclasts (Holloway, W., and M.T. Gillespie, unpublished data). These latter two sets of observations contrast with the effects of IFN-, which promotes the proliferation of macrophages in vitro (35) and inhibits resorption by freshly isolated osteoclasts (36). Finally, our finding that IFN- submaximally inhibited OCL formation during both the proliferative (days 0–3) and the maturation (days 3–6) phases of the coculture indicated that the inhibitory actions of IL-18 on OCL formation do not involve IFN- as an intermediate.
On the other hand, these results indicate that GM–CSF might be a molecular intermediate in the inhibitory effect of IL-18 on osteoclastogenesis. This arises from the fact that a neutralizing antibody against GM–CSF was able to prevent IL-18 inhibition of OCL formation. Furthermore, the finding that the effect of IL-18 in our experiments was on the early phase of the cocultures, in which proliferation of hemopoietic precursors is the dominant process, is entirely consistent with GM–CSF involvement. Conflicting reports exist for the action of GM–CSF on the production of osteoclasts in vitro. In human bone marrow cultures, GM– CSF stimulated the formation of multinucleated cells (37), whereas in mouse marrow cultures GM–CSF inhibited OCL formation (16, 26, 32–34). Our results in the cocultures are in accordance with the latter.
IL-18 shares substantial identity with IL-1, including the IL-1 signature-like sequence (F-X(12)-F-X-S-X(6)-F-L; 23) and secondary structure (38). These properties suggested that IL-18 may be functionally similar to the IL-1 family of cytokines. Thus, it was foreseeable that IL-18 may bind to the IL-1 receptor and could potentially inhibit OCL formation in a manner akin to the IL-1 receptor antagonist (39). Indeed, the suggestion was made that IGIF (22) should be called IL-1 (39). However, attempts to displace IL-18 inhibition of OCL formation with excess of IL-1β were unsuccessful, indicating that either IL-18 binds to a receptor distinct from that for IL-1 or that it has a higher affinity for the IL-1 receptor than IL-1β. The identity of the IL-18 receptor remains to be established.
The finding that IL-18 mRNA was elevated in OCLnoninductive stromal cells, and that IL-18 could inhibit OCL formation, implies that IL-18, and by inference GM– CSF, participates in local control of osteoclastogenesis. Thus, the regulation of IL-18 and GM–CSF expression in the bone microenvironment by circulating hormones or by other local factors may function to limit the generation of osteoclasts.
|
Acknowledgments
|
|---|
This work was supported by a Program Grant from the National Health and Medical Research Council (NHMRC) Australia (T.J. Martin and M.T. Gillespie) and by the Medical Research Council (T.J. Chambers).
Submitted: 19 November 1996
Revised: 6 January 1997
M.T. Gillespie is a Research Fellow of the NHMRC Australia and N. Udagawa was a recipient of a C.R. Roper Fellowship from The University of Melbourne.
N. Udagawa and N.J. Horwood contributed equally to this work.
1 Abbreviations used in this paper: 1,25(OH)2 D3, 1,25-dihydroxyvitamin D3; GM–CSF, neutralizing antibody to GM–CSF; IFN-, neutralizing antibody to IFN-; ddPCR, differential display PCR; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GM–CSF, granulocyte/macrophage colony-stimulating factor; IFN- R–/–, IFN- receptor type II knockout; IGIF, interferon--inducing factor; OCL, osteoclast-like multinucleated cells; PGE2, prostaglandin E2; PTH, parathyroid hormone; RT, reverse transcription (or transcribed); TRAP, tartrate resistant acid phosphatase.
|
References
|
|---|
1 Suda, T., N. Takahashi, and T.J. Martin. 1995. Modulation of osteoclast differentiation: update. In Endocrine Review Monographs. Vol. 4. D.D. Bikle and A. Negrovilar, editors. Endocrine Society, Bethesda, MD. 266–270.
2 Martin TJ & Ng KW. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity, J Cell Biochem, 1994, 56, 357–366.[Medline]
3 Suda, T., N. Udagawa, and N. Takahashi. 1996. Cells of bone: osteoclast generation. In Principles of Bone Biology. J.P. Billezikian, L.G. Raisz, G.A. Rodan, editors. Academic Press, San Diego, CA. 87–102.
4 Roodman GD. Advances in bone biology: the osteoclast, Endocrine Rev, 1996, 17, 308–332.[Abstract/Free Full Text]
5 Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T et al.. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6, Proc Natl Acad Sci USA, 1993, 90, 11924–11928.[Abstract/Free Full Text]
6 Udagawa N, Takahashi N, Katagiri T, Tamura T, Wada S, Findlay DM, Martin TJ, Hirota H, Taga T, Kishimoto T et al.. IL-6 induction of osteoclast differentiation depends upon IL-6 receptors expressed on osteoblastic cells, but not on osteoclast progenitors, J Exp Med, 1995, 182, 1461–1468.[Abstract/Free Full Text]
7 Romas E, Udagawa N, Zhou H, Tamura T, Saito M, Taga T, Hilton DJ, Suda T, Ng KW & Martin TJ. The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures, J Exp Med, 1996, 183, 2581–2592.[Abstract/Free Full Text]
8 Suda T, Takahashi N & Martin TJ. Modulation of osteoclast differentiation, Endocrine Rev, 1992, 13, 66–88.[Abstract/Free Full Text]
9 Shioi A, Teitelbaum SL, Ross FP, Suzuki H, Ohara J & Lacey DL. Interleukin 4 inhibits murine osteoclast formation in vitro, J Cell Biochem, 1991, 47, 272–277.[Medline]
10 Lacey DL, Erdmann JM, Teitelbaum SL, Tan H-L, Ohara J & Shioi A. Interleukin 4, interferon-, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages, Endocrinology, 1995, 136, 2367–2376.[Abstract]
11 Xu LX, Kukita T, Kukita A, Otsuka T, Niho Y & Iijima T. Interleukin-10 selectively inhibits osteoclastogenesis by inhibiting differentiation of osteoclast progenitors into preoteoclast-like cells, J Cell Physiol, 1995, 165, 624–629.[Medline]
12 McHugh, K.P., S.L. Teitelbaum, and F.P. Ross. 1995. Interleukin-13, like interleukin-4, modulates murine osteoclastogenesis and expression of the integrin ,β3 on osteoclast precursors. J. Bone Miner. Res. 10(Suppl.):S487.
13 Takahashi N, Mundy GR & Roodman GD. Recombinant human interferon- inhibits formation of human osteoclast-like cells, J Immunol, 1986, 137, 3544–3549.[Abstract]
14 Horowitz, M.C., and J.A. Lorenzo. 1996. Local regulators of bone: IL-1, TNF, lymphotoxin, interferon-, IL-8, IL-10, IL-4, the LIF/IL-6 family, and additional cytokines. In Principles of Bone Biology. J.P. Billezikian, L.G. Raisz, G.A. Rodan, editors. Academic Press, San Diego, CA. 687–700.
15 Nakano Y, Watanabe K, Morimoto I, Okada Y, Ura K, Sato K, Kasono K, Nakamura T & Eto S. Interleukin-4 inhibits spontaneous and parathyroid hormone– related protein-stimulated osteoclast formation in mice, J Bone Miner Res, 1994, 9, 1533–1539.[Medline]
16 Hattersley G & Chambers TJ. The effects of interleukin 3, granulocyte–macrophage– and macrophage–colony stimulating factors on osteoclast differentiation from mouse hemopoietic tissue, J Cell Physiol, 1990, 142, 201–209.[Medline]
17 Owens JM, Gallagher AC & Chambers TJ. IL-10 modulates formation of osteoclasts in murine hemopoietic cultures, J Immunol, 1996, 157, 936–940.[Abstract]
18 Udagawa N, Takahashi N, Akatsu T, Sasaki T, Yamaguchi A, Kodama H, Martin TJ & Suda T. The bone marrow–derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells, Endocrinology, 1989, 125, 1805–1813.[Abstract/Free Full Text]
19 Chambers TJ, Owens JM, Hattersley G, Jat PS & Noble MD. Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2KbtsA58transgenic mouse, Proc Natl Acad Sci USA, 1993, 90, 5578–5582.[Abstract/Free Full Text]
20 Owens JM, Gallagher AC & Chambers TJ. Bone cells required for osteoclastic resorption but not for osteoclastic differentiation, Biochem Biophys Res Commun, 1996, 222, 225–229.[Medline]
21 Liang P & Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction, Science (Wash DC), 1992, 257, 967–971.[Abstract/Free Full Text]
22 Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K et al.. Cloning of a new cytokine that induces IFN- production by T cells, Nature (Lond), 1995, 378, 88–91.[Medline]
23 Ushio S, Namba M, Okura T, Hattori K, Nukada Y, Akita K, Tanabe F, Konishi K, Micallef M, Fujii M et al.. Cloning of the cDNA for human IFN--inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein, J Immunol, 1996, 156, 4274–4279.[Abstract]
24 Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, Kamijo R, Vilcek J, Zinkernagel RM & Aguet M. Immune response in mice that lack the interferon- receptor, Science (Wash DC), 1993, 259, 1742–1745.[Abstract/Free Full Text]
25 Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, Martin TJ & Suda T. Osteoblastic cells are involved in osteoclast formation, Endocrinology, 1988, 123, 2600–2602.[Abstract/Free Full Text]
26 Takahashi N, Udagawa N, Akatsu T, Tanaka H, Shionome M & Suda T. Role of colony-stimulating factors in osteoclast development, J Bone Miner Res, 1991, 6, 977–985.[Medline]
27 Southby J, Murphy LM, Martin TJ & Gillespie MT. Cell-specific and regulator-induced promoter usage and messenger ribonucleic acid splicing for parathyroid hormone–related protein, Endocrinology, 1996, 137, 1349–1357.[Abstract]
28 Traianedes K, Findlay DM, Martin TJ & Gillespie MT. Modulation of the signal recognition particle 54-kDa subunit (SRP54) in rat preosteoblasts by the extracellular matrix, J Biol Chem, 1995, 270, 20891–20894.[Abstract/Free Full Text]
29 Tso JY, Sun X-H, Kao T-h, Reece KS & Wu R. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexicity and molecular evolution of the gene, Nucleic Acids Res, 1985, 13, 2485–2502.[Abstract/Free Full Text]
30 Suda N, Gillespie MT, Traianedes K, Zhou H, Ho PWM, Hards DK, Allan EH, Martin TJ & Moseley JM. Expression of parathyroid hormone–related protein in cells of osteoblast lineage, J Cell Physiol, 1996, 166, 94–104.[Medline]
31 Kurihara N & Roodman GD. Interferon- and - inhibit interleukin-1 β-stimulated osteoclast-like cell formation in long-term human marrow cultures, J Interferon Res, 1990, 10, 541–547.[Medline]
32 Takahashi N, Udagawa N, Akatsu T, Tanaka H, Isogai Y & Suda T. Deficiency of osteoclasts in osteopetrotic mice is due to a defect in the local microenvironment provided by osteoblastic cells, Endocrinology, 1991, 128, 1792–1796.[Abstract/Free Full Text]
33 Shinar DM, Sato M & Rodan GA. The effect of hemopoietic growth factors on the generation of osteoclastlike cells in mouse bone marrow cultures, Endocrinology, 1990, 126, 1728–1735.[Abstract/Free Full Text]
34 Shuto T, Kukita T, Hirata M, Jimi E & Koga T. Dexamethasone stimulates osteoclast-like cell formation by inhibiting granulocyte–macrophage colony-stimulating factor production in mouse bone marrow cultures, Endocrinology, 1994, 134, 1121–1126.[Abstract/Free Full Text]
35 Vairo G, Argyriou S, Knight KR & Hamilton JA. Inhibition of colony-stimulated macrophage proliferation by tumor necrosis factor-, IFN-, and lipopolysaccharide is not due to a general loss of responsiveness to growth factor, J Immunol, 1991, 146, 3469–3477.[Abstract]
36 Gowen M, Nedwin GE & Mundy GR. Preferential inhibition of cytokine-stimulated bone resorption by recombinant interferon gamma, J Bone Miner Res, 1986, 1, 469–474.[Medline]
37 MacDonald BR, Mundy GR, Clark S, Wang EA, Kuehl TJ, Stanley ER & Roodman GD. Effects of human recombinant CSF–GM and highly purified CSF-1 on the formation of multinucleated cells with osteoclast characteristics in long-term bone marrow cultures, J Bone Mineral Res, 1986, 1, 227–233.[Medline]
38 Bazan JF, Timans JC & Kastelein RA. A newly defined interleukin-1? , Nature (Lond), 1996, 379, 591, .[Medline]
39 Kitazawa R, Kimble RB, Vannice JL, Kung VT & Pacifici R. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice, J Clin Invest, 1994, 94, 2397–2406.[Medline]
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
-
Adam, N., Rabe, B., Suthaus, J., Grotzinger, J., Rose-John, S., Scheller, J.
(2009). Unraveling Viral Interleukin-6 Binding to gp130 and Activation of STAT-Signaling Pathways Independently of the Interleukin-6 Receptor. J. Virol.
83: 5117-5126
[Abstract]
[Full Text]
-
Axmann, R, Herman, S, Zaiss, M, Franz, S, Polzer, K, Zwerina, J, Herrmann, M, Smolen, J, Schett, G
(2008). CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis
67: 1603-1609
[Abstract]
[Full Text]
-
Carroll, H. P., Paunovic, V., Gadina, M.
(2008). Signalling, inflammation and arthritis: Crossed signals: the role of interleukin-15 and -18 in autoimmunity. Rheumatology (Oxford)
47: 1269-1277
[Abstract]
[Full Text]
-
Lorenzo, J., Horowitz, M., Choi, Y.
(2008). Osteoimmunology: Interactions of the Bone and Immune System. Endocr. Rev.
29: 403-440
[Abstract]
[Full Text]
-
Kang, Y. J., Chen, J., Otsuka, M., Mols, J., Ren, S., Wang, Y., Han, J.
(2008). Macrophage Deletion of p38{alpha} Partially Impairs Lipopolysaccharide-Induced Cellular Activation. J. Immunol.
180: 5075-5082
[Abstract]
[Full Text]
-
Raggatt, L. J., Qin, L., Tamasi, J., Jefcoat, S. C. Jr., Shimizu, E., Selvamurugan, N., Liew, F. Y., Bevelock, L., Feyen, J. H. M., Partridge, N. C.
(2008). Interleukin-18 Is Regulated by Parathyroid Hormone and Is Required for Its Bone Anabolic Actions. J. Biol. Chem.
283: 6790-6798
[Abstract]
[Full Text]
-
Lymperi, S., Horwood, N., Marley, S., Gordon, M. Y., Cope, A. P., Dazzi, F.
(2008). Strontium can increase some osteoblasts without increasing hematopoietic stem cells. Blood
111: 1173-1181
[Abstract]
[Full Text]
-
Price, J. D., Simpfendorfer, K. R., Mantena, R. R., Holden, J., Heath, W. R., van Rooijen, N., Strugnell, R. A., Wijburg, O. L. C.
(2007). Gamma Interferon-Independent Effects of Interleukin-12 on Immunity to Salmonella enterica Serovar Typhimurium. Infect. Immun.
75: 5753-5762
[Abstract]
[Full Text]
-
Dai, S.-M., Shan, Z.-Z., Xu, H., Nishioka, K.
(2007). Cellular targets of interleukin-18 in rheumatoid arthritis. Ann Rheum Dis
66: 1411-1418
[Abstract]
[Full Text]
-
Kim, K., Lee, J., Kim, J. H., Jin, H. M., Zhou, B., Lee, S. Y., Kim, N.
(2007). Protein Inhibitor of Activated STAT 3 Modulates Osteoclastogenesis by Down-Regulation of NFATc1 and Osteoclast-Associated Receptor. J. Immunol.
178: 5588-5594
[Abstract]
[Full Text]
-
Sato, K., Suematsu, A., Okamoto, K., Yamaguchi, A., Morishita, Y., Kadono, Y., Tanaka, S., Kodama, T., Akira, S., Iwakura, Y., Cua, D. J., Takayanagi, H.
(2006). Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. JEM
203: 2673-2682
[Abstract]
[Full Text]
-
Mochizuki, A., Takami, M., Kawawa, T., Suzumoto, R., Sasaki, T., Shiba, A., Tsukasaki, H., Zhao, B., Yasuhara, R., Suzawa, T., Miyamoto, Y., Choi, Y., Kamijo, R.
(2006). Identification and Characterization of the Precursors Committed to Osteoclasts Induced by TNF-Related Activation-Induced Cytokine/Receptor Activator of NF-{kappa}B Ligand. J. Immunol.
177: 4360-4368
[Abstract]
[Full Text]
-
Kovaleva, M., Bussmeyer, I., Rabe, B., Grotzinger, J., Sudarman, E., Eichler, J., Conrad, U., Rose-John, S., Scheller, J.
(2006). Abrogation of Viral Interleukin-6 (vIL-6)-Induced Signaling by Intracellular Retention and Neutralization of vIL-6 with an Anti-vIL-6 Single-Chain Antibody Selected by Phage Display.. J. Virol.
80: 8510-8520
[Abstract]
[Full Text]
-
Fujimura, Y., Hotokezaka, H., Ohara, N., Naito, M., Sakai, E., Yoshimura, M., Narita, Y., Kitaura, H., Yoshida, N., Nakayama, K.
(2006). The Hemoglobin Receptor Protein of Porphyromonas gingivalis Inhibits Receptor Activator NF-{kappa}B Ligand-Induced Osteoclastogenesis from Bone Marrow Macrophages.. Infect. Immun.
74: 2544-2551
[Abstract]
[Full Text]
-
Fisher, J. L., Thomas-Mudge, R. J., Elliott, J., Hards, D. K., Sims, N. A., Slavin, J., Martin, T. J., Gillespie, M. T.
(2006). Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically.. Cancer Res.
66: 3620-3628
[Abstract]
[Full Text]
-
Chandrasekar, B., Mummidi, S., Valente, A. J., Patel, D. N., Bailey, S. R., Freeman, G. L., Hatano, M., Tokuhisa, T., Jensen, L. E.
(2005). The Pro-atherogenic Cytokine Interleukin-18 Induces CXCL16 Expression in Rat Aortic Smooth Muscle Cells via MyD88, Interleukin-1 Receptor-associated Kinase, Tumor Necrosis Factor Receptor-associated Factor 6, c-Src, Phosphatidylinositol 3-Kinase, Akt, c-Jun N-terminal Kinase, and Activator Protein-1 Signaling. J. Biol. Chem.
280: 26263-26277
[Abstract]
[Full Text]
-
Tenger, C., Sundborger, A., Jawien, J., Zhou, X.
(2005). IL-18 Accelerates Atherosclerosis Accompanied by Elevation of IFN-{gamma} and CXCL16 Expression Independently of T Cells. Arterioscler. Thromb. Vasc. Bio.
25: 791-796
[Abstract]
[Full Text]
-
Yogesha, S. D., Khapli, S. M., Wani, M. R.
(2005). Interleukin-3 and Granulocyte-Macrophage Colony-stimulating Factor Inhibits Tumor Necrosis Factor (TNF)-{alpha}-induced Osteoclast Differentiation by Down-regulation of Expression of TNF Receptors 1 and 2. J. Biol. Chem.
280: 11759-11769
[Abstract]
[Full Text]
-
Dai, S-M, Nishioka, K, Yudoh, K
(2004). Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1{beta} and tumour necrosis factor {alpha}. Ann Rheum Dis
63: 1379-1386
[Abstract]
[Full Text]
-
Joosten, L. A.B., Smeets, R. L., Koenders, M. I., van den Bersselaar, L. A.M., Helsen, M. M.A., Oppers-Walgreen, B., Lubberts, E., Iwakura, Y., van de Loo, F. A.J., van den Berg, W. B.
(2004). Interleukin-18 Promotes Joint Inflammation and Induces Interleukin-1-Driven Cartilage Destruction. Am. J. Pathol.
165: 959-967
[Abstract]
[Full Text]
-
Wright, K. M., Friedland, J. S.
(2004). Regulation of monocyte chemokine and MMP-9 secretion by proinflammatory cytokines in tuberculous osteomyelitis. J. Leukoc. Biol.
75: 1086-1092
[Abstract]
[Full Text]
-
O'Gradaigh, D., Compston, J. E.
(2004). T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion. Rheumatology (Oxford)
43: 122-130
[Full Text]
-
Kaser, A., Kaser, S., Kaneider, N. C., Enrich, B., Wiedermann, C. J., Tilg, H.
(2004). Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression. Blood
103: 648-655
[Abstract]
[Full Text]
-
Sasaki, H., Balto, K., Kawashima, N., Eastcott, J., Hoshino, K., Akira, S., Stashenko, P.
(2004). Gamma Interferon (IFN-{gamma}) and IFN-{gamma}-Inducing Cytokines Interleukin-12 (IL-12) and IL-18 Do Not Augment Infection-Stimulated Bone Resorption In Vivo. CVI
11: 106-110
[Abstract]
[Full Text]
-
Cannetti, C. A., Leung, B. P., Culshaw, S., McInnes, I. B., Cunha, F. Q., Liew, F. Y.
(2003). IL-18 Enhances Collagen-Induced Arthritis by Recruiting Neutrophils Via TNF-{alpha} and Leukotriene B4. J. Immunol.
171: 1009-1015
[Abstract]
[Full Text]
-
Takeda, N., Arima, M., Tsuruoka, N., Okada, S., Hatano, M., Sakamoto, A., Kohno, Y., Tokuhisa, T.
(2003). Bcl6 Is a Transcriptional Repressor for the IL-18 Gene. J. Immunol.
171: 426-431
[Abstract]
[Full Text]
-
Cornish, J., Gillespie, M. T., Callon, K. E., Horwood, N. J., Moseley, J. M., Reid, I. R.
(2003). Interleukin-18 Is a Novel Mitogen of Osteogenic and Chondrogenic Cells. Endocrinology
144: 1194-1201
[Abstract]
[Full Text]
-
Schrum, L. W., Marriott, I., Butler, B. R., Thomas, E. K., Hudson, M. C., Bost, K. L.
(2003). Functional CD40 Expression Induced following Bacterial Infection of Mouse and Human Osteoblasts. Infect. Immun.
71: 1209-1216
[Abstract]
[Full Text]
-
Gracie, J. A., Robertson, S. E., McInnes, I. B.
(2003). Interleukin-18. J. Leukoc. Biol.
73: 213-224
[Abstract]
[Full Text]
-
Cappellen, D., Luong-Nguyen, N.-H., Bongiovanni, S., Grenet, O., Wanke, C., Susa, M.
(2002). Transcriptional Program of Mouse Osteoclast Differentiation Governed by the Macrophage Colony-stimulating Factor and the Ligand for the Receptor Activator of NFkappa B. J. Biol. Chem.
277: 21971-21982
[Abstract]
[Full Text]
-
Gerdes, N., Sukhova, G. K., Libby, P., Reynolds, R. S., Young, J. L., Schonbeck, U.
(2002). Expression of Interleukin (IL)-18 and Functional IL-18 Receptor on Human Vascular Endothelial Cells, Smooth Muscle Cells, and Macrophages: Implications for Atherogenesis. JEM
195: 245-257
[Abstract]
[Full Text]
-
Jordan, J. A., Guo, R.-F., Yun, E. C., Sarma, V., Warner, R. L., Crouch, L. D., Senaldi, G., Ulich, T. R., Ward, P. A.
(2001). Role of IL-18 in Acute Lung Inflammation. J. Immunol.
167: 7060-7068
[Abstract]
[Full Text]
-
Sugawara, S., Uehara, A., Nochi, T., Yamaguchi, T., Ueda, H., Sugiyama, A., Hanzawa, K., Kumagai, K., Okamura, H., Takada, H.
(2001). Neutrophil Proteinase 3-Mediated Induction of Bioactive IL-18 Secretion by Human Oral Epithelial Cells. J. Immunol.
167: 6568-6575
[Abstract]
[Full Text]
-
Esfandiari, E., McInnes, I. B., Lindop, G., Huang, F.-P., Field, M., Komai-Koma, M., Wei, X.-q., Liew, F. Y.
(2001). A Proinflammatory Role of IL-18 in the Development of Spontaneous Autoimmune Disease. J. Immunol.
167: 5338-5347
[Abstract]
[Full Text]
-
Miyamoto, T., Ohneda, O., Arai, F., Iwamoto, K., Okada, S., Takagi, K., Anderson, D. M., Suda, T.
(2001). Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood
98: 2544-2554
[Abstract]
[Full Text]
-
Ogura, T., Ueda, H., Hosohara, K., Tsuji, R., Nagata, Y., Kashiwamura, S.-i., Okamura, H.
(2001). Interleukin-18 stimulates hematopoietic cytokine and growth factor formation and augments circulating granulocytes in mice. Blood
98: 2101-2107
[Abstract]
[Full Text]
-
Leung, B. P., Culshaw, S., Gracie, J. A., Hunter, D., Canetti, C. A., Campbell, C., Cunha, F., Liew, F. Y., McInnes, I. B.
(2001). A Role for IL-18 in Neutrophil Activation. J. Immunol.
167: 2879-2886
[Abstract]
[Full Text]
-
Helmby, H., Takeda, K., Akira, S., Grencis, R. K.
(2001). Interleukin (Il)-18 Promotes the Development of Chronic Gastrointestinal Helminth Infection by Downregulating IL-13. JEM
194: 355-364
[Abstract]
[Full Text]
-
Swain, S. L.
(2001). Interleukin 18: Tipping the Balance towards a T Helper Cell 1 Response. JEM
194: f11-f14
[Full Text]
-
Itoh, K., Udagawa, N., Katagiri, T., Iemura, S., Ueno, N., Yasuda, H., Higashio, K., Quinn, J. M. W., Gillespie, M. T., Martin, T. J., Suda, T., Takahashi, N.
(2001). Bone Morphogenetic Protein 2 Stimulates Osteoclast Differentiation and Survival Supported by Receptor Activator of Nuclear Factor-{kappa}B Ligand. Endocrinology
142: 3656-3662
[Abstract]
[Full Text]
-
Park, C. C., Morel, J. C. M., Amin, M. A., Connors, M. A., Harlow, L. A., Koch, A. E.
(2001). Evidence of IL-18 as a Novel Angiogenic Mediator. J. Immunol.
167: 1644-1653
[Abstract]
[Full Text]
-
Horwood, N. J., Elliott, J., Martin, T. J., Gillespie, M. T.
(2001). IL-12 Alone and in Synergy with IL-18 Inhibits Osteoclast Formation In Vitro. J. Immunol.
166: 4915-4921
[Abstract]
[Full Text]
-
Moller, B., Kukoc-Zivojnov, N., Kessler, U., Rehart, S., Kaltwasser, J. P., Hoelzer, D., Kalina, U., Ottmann, O. G.
(2001). Expression of interleukin-18 and its monokine-directed function in rheumatoid arthritis. Rheumatology (Oxford)
40: 302-309
[Abstract]
[Full Text]
-
Jiang, H.-R., Wei, X.-q., Niedbala, W., Lumsden, L., Liew, F. Y., Forrester, J. V.
(2001). IL-18 Not Required for IRBP Peptide-Induced EAU: Studies in Gene-Deficient Mice. IOVS
42: 177-182
[Abstract]
[Full Text]
-
Sugama, S., Kim, Y., Baker, H., Tinti, C., Kim, H., Joh, T. H., Conti, B.
(2000). Tissue-Specific Expression of Rat IL-18 Gene and Response to Adrenocorticotropic Hormone Treatment. J. Immunol.
165: 6287-6292
[Abstract]
[Full Text]
-
Joosten, L. A. B., van de Loo, F. A. J., Lubberts, E., Helsen, M. M. A., Netea, M. G., van der Meer, J. W. M., Dinarello, C. A., van den Berg, W. B.
(2000). An IFN-{gamma}-Independent Proinflammatory Role of IL-18 in Murine Streptococcal Cell Wall Arthritis. J. Immunol.
165: 6553-6558
[Abstract]
[Full Text]
-
Narita, M., Tanaka, H., Abe, S., Yamada, S., Kubota, M., Togashi, T.
(2000). Close Association between Pulmonary Disease Manifestation in Mycoplasma pneumoniae Infection and Enhanced Local Production of Interleukin-18 in the Lung, Independent of Gamma Interferon. CVI
7: 909-914
[Abstract]
[Full Text]
-
Fox, S. W., Fuller, K., Bayley, K. E., Lean, J. M., Chambers, T. J.
(2000). TGF-{beta}1 and IFN-{gamma} Direct Macrophage Activation by TNF-{alpha} to Osteoclastic or Cytocidal Phenotype. J. Immunol.
165: 4957-4963
[Abstract]
[Full Text]
-
Grcevic, D., Lee, S.-K., Marusic, A., Lorenzo, J. A.
(2000). Depletion of CD4 and CD8 T Lymphocytes in Mice In Vivo Enhances 1,25-Dihydroxyvitamin D3-Stimulated Osteoclast-Like Cell Formation In Vitro by a Mechanism That Is Dependent on Prostaglandin Synthesis. J. Immunol.
165: 4231-4238
[Abstract]
[Full Text]
-
Kim, Y.-M., Im, J. Y., Han, S. H., Kang, H. S., Choi, I.
(2000). IFN-{gamma} Up-Regulates IL-18 Gene Expression Via IFN Consensus Sequence-Binding Protein and Activator Protein-1 Elements in Macrophages. J. Immunol.
165: 3198-3205
[Abstract]
[Full Text]
-
Bost, K. L., Bento, J. L., Ellington, J. K., Marriott, I., Hudson, M. C.
(2000). Induction of Colony-Stimulating Factor Expression following Staphylococcus or Salmonella Interaction with Mouse or Human Osteoblasts. Infect. Immun.
68: 5075-5083
[Abstract]
[Full Text]
-
Leung, B. P., McInnes, I. B., Esfandiari, E., Wei, X.-Q., Liew, F. Y.
(2000). Combined Effects of IL-12 and IL-18 on the Induction of Collagen-Induced Arthritis. J. Immunol.
164: 6495-6502
[Abstract]
[Full Text]
-
Li, X., Okada, Y., Pilbeam, C. C., Lorenzo, J. A., Kennedy, C. R. J., Breyer, R. M., Raisz, L. G.
(2000). Knockout of the Murine Prostaglandin EP2 Receptor Impairs Osteoclastogenesis in Vitro. Endocrinology
141: 2054-2061
[Abstract]
[Full Text]
-
Cho, D., Song, H., Kim, Y. M., Houh, D., Hur, D. Y., Park, H., Yoon, D., Pyun, K. H., Lee, W. J., Kurimoto, M., Kim, Y. B., Kim, Y. S., Choi, I.
(2000). Endogenous Interleukin-18 Modulates Immune Escape of Murine Melanoma Cells by Regulating the Expression of Fas Ligand and Reactive Oxygen Intermediates. Cancer Res.
60: 2703-2709
[Abstract]
[Full Text]
-
Manolagas, S. C.
(2000). Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis. Endocr. Rev.
21: 115-137
[Abstract]
[Full Text]
-
CAO, R., FARNEBO, J., KURIMOTO, M., CAO, Y.
(1999). Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J.
13: 2195-2202
[Abstract]
[Full Text]
-
Thomas, R. J., Guise, T. A., Yin, J. J., Elliott, J., Horwood, N. J., Martin, T. J., Gillespie, M. T.
(1999). Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation. Endocrinology
140: 4451-4458
[Abstract]
[Full Text]
-
Wei, X.-q., Leung, B. P., Niedbala, W., Piedrafita, D., Feng, G.-j., Sweet, M., Dobbie, L., Smith, A. J. H., Liew, F. Y.
(1999). Altered Immune Responses and Susceptibility to Leishmania major and Staphylococcus aureus Infection in IL-18-Deficient Mice. J. Immunol.
163: 2821-2828
[Abstract]
[Full Text]
-
Kim, Y.-M., Kang, H.-S., Paik, S.-G., Pyun, K.-H., Anderson, K. L., Torbett, B. E., Choi, I.
(1999). Roles of IFN Consensus Sequence Binding Protein and PU.1 in Regulating IL-18 Gene Expression. J. Immunol.
163: 2000-2007
[Abstract]
[Full Text]
-
O'Brien, C. A., Gubrij, I., Lin, S.-C., Saylors, R. L., Manolagas, S. C.
(1999). STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-kappa B Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-1 but Not 1,25-Dihydroxyvitamin D3 or Parathyroid Hormone. J. Biol. Chem.
274: 19301-19308
[Abstract]
[Full Text]
-
Matsuzaki, K., Katayama, K., Takahashi, Y., Nakamura, I., Udagawa, N., Tsurukai, T., Nishinakamura, R., Toyama, Y., Yabe, Y., Hori, M., Takahashi, N., Suda, T.
(1999). Human Osteoclast-Like Cells Are Formed from Peripheral Blood Mononuclear Cells in a Coculture with SaOS-2 Cells Transfected with the Parathyroid Hormone (PTH)/PTH-Related Protein Receptor Gene. Endocrinology
140: 925-932
[Abstract]
[Full Text]
-
Olee, T., Hashimoto, S., Quach, J., Lotz, M.
(1999). IL-18 Is Produced by Articular Chondrocytes and Induces Proinflammatory and Catabolic Responses. J. Immunol.
162: 1096-1100
[Abstract]
[Full Text]
-
Born, T. L., Thomassen, E., Bird, T. A., Sims, J. E.
(1998). Cloning of a Novel Receptor Subunit, AcPL, Required for Interleukin-18 Signaling. J. Biol. Chem.
273: 29445-29450
[Abstract]
[Full Text]
-
Torigoe, K., Ushio, S., Okura, T., Kobayashi, S., Taniai, M., Kunikata, T., Murakami, T., Sanou, O., Kojima, H., Fujii, M., Ohta, T., Ikeda, M., Ikegami, H., Kurimoto, M.
(1997). Purification and Characterization of the Human Interleukin-18 Receptor. J. Biol. Chem.
272: 25737-25742
[Abstract]
[Full Text]
Top
Abstract
Materials and Methods
